High Viral Suppression Found for Patients With HIV Receiving Long-Acting LEN/CAB

FRIDAY, Oct. 16, 2026-- Among patients with HIV who received long-acting lenacapavir (LEN)/cabotegravir (CAB), those with baseline viral suppression (VS) maintained VS and those without achieved VS by 13 weeks, according to a research letter...